Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127 - 37; http://dx.doi.org/10.1038/35052073; PMID: 11252954
   PubMed Web of Science ®Google Scholar
• Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312:1175 - 8; http://dx.doi.org/10.1126/science.1125951; PMID: 16728632
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413 - 5; http://dx.doi.org/10.4161/mabs.19931; PMID: 22531442
   PubMed Web of Science ®Google Scholar
• Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, Grosse R. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. J Cell Biochem 1992; 49:157 - 65; http://dx.doi.org/10.1002/jcb.240490208; PMID: 1400622
   PubMed Web of Science ®Google Scholar
• Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71 - 81; http://dx.doi.org/10.1016/S1380-2933(97)00065-1; PMID: 9154469
   PubMedGoogle Scholar
• Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343 - 9; http://dx.doi.org/10.4161/cbt.9.5.10981; PMID: 20448462
   PubMed Web of Science ®Google Scholar
• Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 2013; 13:299; http://dx.doi.org/10.1186/1471-2407-13-299; PMID: 23782513
   PubMed Web of Science ®Google Scholar
• Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012; 13:600 - 5; http://dx.doi.org/10.4161/cbt.19849; PMID: 22555809
   PubMed Web of Science ®Google Scholar
• Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010; 4:289 - 98; PMID: 21116327
   PubMedGoogle Scholar
• Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012; 30:1138 - 43; http://dx.doi.org/10.1007/s10637-010-9619-8; PMID: 21170759
   PubMed Web of Science ®Google Scholar
• Allan DGP. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005; 10:760 - 1; http://dx.doi.org/10.1634/theoncologist.10-9-760; PMID: 16249358
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567 - 75; http://dx.doi.org/10.1002/ijc.10647; PMID: 12237899
   PubMed Web of Science ®Google Scholar
• Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, Montero E. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007; 26:423 - 31; http://dx.doi.org/10.1089/hyb.2007.0516; PMID: 18158788
   PubMed Web of Science ®Google Scholar
• Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-4518; PMID: 19584289
   PubMed Web of Science ®Google Scholar
• Chao G, Cochran JR, Wittrup KD. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol 2004; 342:539 - 50; http://dx.doi.org/10.1016/j.jmb.2004.07.053; PMID: 15327953
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301 - 11; http://dx.doi.org/10.1016/j.ccr.2005.03.003; PMID: 15837620
   PubMed Web of Science ®Google Scholar
• Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16:216 - 27; http://dx.doi.org/10.1016/j.str.2007.11.009; PMID: 18275813
   PubMed Web of Science ®Google Scholar
• Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, Cocklin S, Williams JC, Papazoglou E, Rodeck U. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008; 7:726 - 33; http://dx.doi.org/10.4161/cbt.7.5.6097; PMID: 18424917
   PubMed Web of Science ®Google Scholar
• Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011; 3:584 - 95; http://dx.doi.org/10.4161/mabs.3.6.17955; PMID: 22123060
   PubMed Web of Science ®Google Scholar
• Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012; 14:1023 - 31; PMID: 23226096
   PubMed Web of Science ®Google Scholar
• Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221 - 3; http://dx.doi.org/10.1038/nm.2609; PMID: 22270724
   PubMed Web of Science ®Google Scholar
• Ramírez BS, Pestana ES, Hidalgo GG, García TH, Rodríguez RP, Ullrich A, Férnandez LE. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 2006; 119:2190 - 9; http://dx.doi.org/10.1002/ijc.22085; PMID: 16841332
   PubMed Web of Science ®Google Scholar
• Cochran JR, Kim Y-S, Olsen MJ, Bhandari R, Wittrup KD. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods 2004; 287:147 - 58; http://dx.doi.org/10.1016/j.jim.2004.01.024; PMID: 15099763
   PubMed Web of Science ®Google Scholar
• Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1:511 - 29; PMID: 6094961
   PubMedGoogle Scholar
• Van den Burg B, Dijkstra BW, Vriend G, Van der Vinne B, Venema G, Eijsink VG. Protein stabilization by hydrophobic interactions at the surface. Eur J Biochem 1994; 220:981 - 5; http://dx.doi.org/10.1111/j.1432-1033.1994.tb18702.x; PMID: 8143751
   PubMedGoogle Scholar
• Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775 - 87; http://dx.doi.org/10.1016/S0092-8674(02)00963-7; PMID: 12297050
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110:763 - 73; http://dx.doi.org/10.1016/S0092-8674(02)00940-6; PMID: 12297049
   PubMed Web of Science ®Google Scholar
• Rojas G, Pupo A, Leon K, Avellanet J, Carmenate T, Sidhu S. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. Immunobiology 2013; 218:105 - 13; http://dx.doi.org/10.1016/j.imbio.2012.02.009; PMID: 22459271
   PubMed Web of Science ®Google Scholar
• Rojas G, Cabrera Infante Y, Pupo A, Carmenate T. Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects. MAbs 2014; 6:273 - 85; http://dx.doi.org/10.4161/mabs.27224; PMID: 24253188
   PubMed Web of Science ®Google Scholar
• Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924 - 7; http://dx.doi.org/10.1126/science.1122927; PMID: 16484453
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schafer W, Georges G, Schwaiger M. mossner, E., Hopfner, K.P., Umaña, P. & Niederfellner, G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationships to functional properties. MAbs 2013; 5:1 - 12; http://dx.doi.org/10.4161/mabs.22771; PMID: 23254906
   PubMed Web of Science ®Google Scholar
• Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 1996; 93:7 - 12; http://dx.doi.org/10.1073/pnas.93.1.7; PMID: 8552677
   PubMed Web of Science ®Google Scholar
• Benjamin DC, Perdue SS. Site-directed mutagenesis in epitope mapping. Methods 1996; 9:508 - 15; http://dx.doi.org/10.1006/meth.1996.0058; PMID: 8812706
   PubMedGoogle Scholar
• Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010; 107:13252 - 7; http://dx.doi.org/10.1073/pnas.0913476107; PMID: 20616078
   PubMed Web of Science ®Google Scholar
• Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010; 29:4517 - 27; http://dx.doi.org/10.1038/onc.2010.195; PMID: 20514015
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005; 97:1663 - 70; http://dx.doi.org/10.1093/jnci/dji373; PMID: 16288119
   PubMed Web of Science ®Google Scholar
• Cardó-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini R. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A 2010; 107:5118 - 23; http://dx.doi.org/10.1073/pnas.0915146107; PMID: 20190183
   PubMed Web of Science ®Google Scholar
• Smith GP, Petrenko VA. Phage Display. Chem Rev 1997; 97:391 - 410; http://dx.doi.org/10.1021/cr960065d; PMID: 11848876
   PubMed Web of Science ®Google Scholar
• Berger C, Krengel U, Stang E, Moreno E, Madshus IH. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J Immunother 2011; 34:550 - 5; http://dx.doi.org/10.1097/CJI.0b013e31822a5ca6; PMID: 21760527
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646 - 54; http://dx.doi.org/10.1200/JCO.2004.03.089; PMID: 15117987
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373 - 82; http://dx.doi.org/10.4161/cbt.11.4.14097; PMID: 21150278
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191; PMID: 16618717
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626 - 34; http://dx.doi.org/10.1200/JCO.2007.14.7116; PMID: 18316791
   PubMed Web of Science ®Google Scholar
• Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010; 9:315 - 8; http://dx.doi.org/10.3816/CCC.2010.n.046; PMID: 21208847
   PubMed Web of Science ®Google Scholar
• Sonoda H, Mekata E, Shimizu T, Endo Y, Tani T. Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. Oncol Lett 2013; 5:1331 - 4; PMID: 23599789
   PubMed Web of Science ®Google Scholar
• Rojas G, Pupo A, Gómez S, Krengel U, Moreno E. Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities. ACS Chem Biol 2013; 8:376 - 86; http://dx.doi.org/10.1021/cb3003754; PMID: 23138862
   PubMed Web of Science ®Google Scholar
• Lamdan H, Gavilondo JV, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Ayala M, Rojas G, Balint RF, et al. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor. Mol Biosyst 2013; 9:2097 - 106; http://dx.doi.org/10.1039/c3mb70136k; PMID: 23702826
   PubMed Web of Science ®Google Scholar
• Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610 - 4; http://dx.doi.org/10.1126/science.1165480; PMID: 19299620
   PubMed Web of Science ®Google Scholar
• Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H, Gray JJ. Benchmarking and analysis of protein docking performance in Rosetta v3.2. PLoS One 2011; 6:e22477; http://dx.doi.org/10.1371/journal.pone.0022477; PMID: 21829626
   PubMed Web of Science ®Google Scholar
• Lee M, Lloyd P, Zhang X, Schallhorn JM, Sugimoto K, Leach AG, Sapiro G, Houk KN. Shapes of antibody binding sites: qualitative and quantitative analyses based on a geomorphic classification scheme. J Org Chem 2006; 71:5082 - 92; http://dx.doi.org/10.1021/jo052659z; PMID: 16808494
   PubMed Web of Science ®Google Scholar
• Vercruysse T, Boons E, Venken T, Vanstreels E, Voet A, Steyaert J, De Maeyer M, Daelemans D. Mapping the binding interface between an HIV-1 inhibiting intrabody and the viral protein Rev. PLoS One 2013; 8:e60259; http://dx.doi.org/10.1371/journal.pone.0060259; PMID: 23565213
   PubMedGoogle Scholar
• Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581 - 97; http://dx.doi.org/10.1016/0022-2836(91)90498-U; PMID: 1748994
   PubMed Web of Science ®Google Scholar
• Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A 1985; 82:488 - 92; http://dx.doi.org/10.1073/pnas.82.2.488; PMID: 3881765
   PubMed Web of Science ®Google Scholar
• Rojas G. Fine epitope mapping based on phage display and extensive mutagenesis of the target antigen. Methods Mol Biol 2014; 1131:447 - 76; http://dx.doi.org/10.1007/978-1-62703-992-5_27; PMID: 24515482
   PubMedGoogle Scholar
• Fellouse FA, Sidhu SS. Making antibodies in bacteria. In Making and using antibodies. A practical handbook 2007. G.C. Howard, and M.R.Kaser, CRC Press, Boca Raton, Florida, pp 157-177.
   Google Scholar
• Gray JJ, Moughon S, Wang C, Schueler-Furman O, Kuhlman B, Rohl CA, Baker D. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol 2003; 331:281 - 99; http://dx.doi.org/10.1016/S0022-2836(03)00670-3; PMID: 12875852
   PubMed Web of Science ®Google Scholar
• Kellogg EH, Leaver-Fay A, Baker D. Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins 2011; 79:830 - 8; http://dx.doi.org/10.1002/prot.22921; PMID: 21287615
   PubMed Web of Science ®Google Scholar